The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global High Potency Active Pharmaceutical Ingredients (APIs) Market Outlook 2024
Synopsis
High Potency Active Pharmaceutical Ingredients (APIs) have higher active level targeting sever diseases such as tumour cells, infected cells, damaged organs than regular medicine elements.
Highly potent APIs are capable of targeting diseased cell selectively and more precisely than other compounds. Increasing incidence of cancer resulted in increasing R&D pertaining to anticancer drugs which thereby propelling the demand for HPAPIs over the forecast period. In addition, rising usage of HPAPI in gynecology & cosmetics are accounted for the further growth.
The global High Potency Active Pharmaceutical Ingredients (APIs) market was valued at US$ 14890 million in 2020 and is expected to reach US$ 20620 million by the end of 2027, growing at a CAGR of 4.7% during 2021-2027.
This report focuses on High Potency Active Pharmaceutical Ingredients (APIs) volume and value at the global level, regional level and company level. From a global perspective, this report represents overall High Potency Active Pharmaceutical Ingredients (APIs) market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, Asia-Pacific, Latin America and Middle East & Africa.
Global High Potency Active Pharmaceutical Ingredients (APIs) Market: Segment Analysis
The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2016 to 2027. Understanding the segments helps in identifying the importance of different factors that aid the market growth.
Segment by Type
Synthetic
Biotech
Segment by Application
Oncology
Hormonal
Glaucoma
Others
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
By Company
Lonza
Novartis International AG
BASF AG
Carbogen Amcis AG
Eli Lilly and Company
Teva Pharmaceutical Industries Ltd
Bristol-Myers Squibb
Pfizer Inc.
Roche Diagnostics.
Hospira Inc
Boehringer Ingelheim
Medtronic
Merck & Co
Bayer AG
Sigma-Aldrich Corporation
Sanofi Aventis.
High Potency Active Pharmaceutical Ingredients (APIs) have higher active level targeting sever diseases such as tumour cells, infected cells, damaged organs than regular medicine elements.
Highly potent APIs are capable of targeting diseased cell selectively and more precisely than other compounds. Increasing incidence of cancer resulted in increasing R&D pertaining to anticancer drugs which thereby propelling the demand for HPAPIs over the forecast period. In addition, rising usage of HPAPI in gynecology & cosmetics are accounted for the further growth.
The global High Potency Active Pharmaceutical Ingredients (APIs) market was valued at US$ 14890 million in 2020 and is expected to reach US$ 20620 million by the end of 2027, growing at a CAGR of 4.7% during 2021-2027.
This report focuses on High Potency Active Pharmaceutical Ingredients (APIs) volume and value at the global level, regional level and company level. From a global perspective, this report represents overall High Potency Active Pharmaceutical Ingredients (APIs) market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, Asia-Pacific, Latin America and Middle East & Africa.
Global High Potency Active Pharmaceutical Ingredients (APIs) Market: Segment Analysis
The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2016 to 2027. Understanding the segments helps in identifying the importance of different factors that aid the market growth.
Segment by Type
Synthetic
Biotech
Segment by Application
Oncology
Hormonal
Glaucoma
Others
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
By Company
Lonza
Novartis International AG
BASF AG
Carbogen Amcis AG
Eli Lilly and Company
Teva Pharmaceutical Industries Ltd
Bristol-Myers Squibb
Pfizer Inc.
Roche Diagnostics.
Hospira Inc
Boehringer Ingelheim
Medtronic
Merck & Co
Bayer AG
Sigma-Aldrich Corporation
Sanofi Aventis.
Index1 High Potency Active Pharmaceutical Ingredients (APIs) Market Overview
1.1 Product Overview and Scope of High Potency Active Pharmaceutical Ingredients (APIs)
1.2 High Potency Active Pharmaceutical Ingredients (APIs) Segment by Type
1.2.1 Global High Potency Active Pharmaceutical Ingredients (APIs) Sales Growth Rate Comparison by Type (2021-2027)
1.2.2 Synthetic
1.2.3 Biotech
1.3 High Potency Active Pharmaceutical Ingredients (APIs) Segment by Application
1.3.1 Global High Potency Active Pharmaceutical Ingredients (APIs) Sales Comparison by Application: (2021-2027)
1.3.2 Oncology
1.3.3 Hormonal
1.3.4 Glaucoma
1.3.5 Others
1.4 Global High Potency Active Pharmaceutical Ingredients (APIs) Market Size Estimates and Forecasts
1.4.1 Global High Potency Active Pharmaceutical Ingredients (APIs) Revenue 2016-2027
1.4.2 Global High Potency Active Pharmaceutical Ingredients (APIs) Sales 2016-2027
1.4.3 High Potency Active Pharmaceutical Ingredients (APIs) Market Size by Region: 2016 Versus 2021 Versus 2027
2 High Potency Active Pharmaceutical Ingredients (APIs) Market Competition by Manufacturers
2.1 Global High Potency Active Pharmaceutical Ingredients (APIs) Sales Market Share by Manufacturers (2016-2021)
2.2 Global High Potency Active Pharmaceutical Ingredients (APIs) Revenue Market Share by Manufacturers (2016-2021)
2.3 Global High Potency Active Pharmaceutical Ingredients (APIs) Average Price by Manufacturers (2016-2021)
2.4 Manufacturers High Potency Active Pharmaceutical Ingredients (APIs) Manufacturing Sites, Area Served, Product Type
2.5 High Potency Active Pharmaceutical Ingredients (APIs) Market Competitive Situation and Trends
2.5.1 High Potency Active Pharmaceutical Ingredients (APIs) Market Concentration Rate
2.5.2 The Global Top 5 and Top 10 Largest High Potency Active Pharmaceutical Ingredients (APIs) Players Market Share by Revenue
2.5.3 Global High Potency Active Pharmaceutical Ingredients (APIs) Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.6 Manufacturers Mergers & Acquisitions, Expansion Plans
3 High Potency Active Pharmaceutical Ingredients (APIs) Retrospective Market Scenario by Region
3.1 Global High Potency Active Pharmaceutical Ingredients (APIs) Retrospective Market Scenario in Sales by Region: 2016-2021
3.2 Global High Potency Active Pharmaceutical Ingredients (APIs) Retrospective Market Scenario in Revenue by Region: 2016-2021
3.3 North America High Potency Active Pharmaceutical Ingredients (APIs) Market Facts & Figures by Country
3.3.1 North America High Potency Active Pharmaceutical Ingredients (APIs) Sales by Country
3.3.2 North America High Potency Active Pharmaceutical Ingredients (APIs) Revenue by Country
3.3.3 U.S.
3.3.4 Canada
3.4 Europe High Potency Active Pharmaceutical Ingredients (APIs) Market Facts & Figures by Country
3.4.1 Europe High Potency Active Pharmaceutical Ingredients (APIs) Sales by Country
3.4.2 Europe High Potency Active Pharmaceutical Ingredients (APIs) Revenue by Country
3.4.3 Germany
3.4.4 France
3.4.5 U.K.
3.4.6 Italy
3.4.7 Russia
3.5 Asia Pacific High Potency Active Pharmaceutical Ingredients (APIs) Market Facts & Figures by Region
3.5.1 Asia Pacific High Potency Active Pharmaceutical Ingredients (APIs) Sales by Region
3.5.2 Asia Pacific High Potency Active Pharmaceutical Ingredients (APIs) Revenue by Region
3.5.3 China
3.5.4 Japan
3.5.5 South Korea
3.5.6 India
3.5.7 Australia
3.5.8 Taiwan
3.5.9 Indonesia
3.5.10 Thailand
3.5.11 Malaysia
3.5.12 Philippines
3.5.13 Vietnam
3.6 Latin America High Potency Active Pharmaceutical Ingredients (APIs) Market Facts & Figures by Country
3.6.1 Latin America High Potency Active Pharmaceutical Ingredients (APIs) Sales by Country
3.6.2 Latin America High Potency Active Pharmaceutical Ingredients (APIs) Revenue by Country
3.6.3 Mexico
3.6.4 Brazil
3.6.5 Argentina
3.7 Middle East and Africa High Potency Active Pharmaceutical Ingredients (APIs) Market Facts & Figures by Country
3.7.1 Middle East and Africa High Potency Active Pharmaceutical Ingredients (APIs) Sales by Country
3.7.2 Middle East and Africa High Potency Active Pharmaceutical Ingredients (APIs) Revenue by Country
3.7.3 Turkey
3.7.4 Saudi Arabia
3.7.5 U.A.E
4 Global High Potency Active Pharmaceutical Ingredients (APIs) Historic Market Analysis by Type
4.1 Global High Potency Active Pharmaceutical Ingredients (APIs) Sales Market Share by Type (2016-2021)
4.2 Global High Potency Active Pharmaceutical Ingredients (APIs) Revenue Market Share by Type (2016-2021)
4.3 Global High Potency Active Pharmaceutical Ingredients (APIs) Price by Type (2016-2021)
5 Global High Potency Active Pharmaceutical Ingredients (APIs) Historic Market Analysis by Application
5.1 Global High Potency Active Pharmaceutical Ingredients (APIs) Sales Market Share by Application (2016-2021)
5.2 Global High Potency Active Pharmaceutical Ingredients (APIs) Revenue Market Share by Application (2016-2021)
5.3 Global High Potency Active Pharmaceutical Ingredients (APIs) Price by Application (2016-2021)
6 Key Companies Profiled
6.1 Lonza
6.1.1 Lonza Corporation Information
6.1.2 Lonza Description and Business Overview
6.1.3 Lonza High Potency Active Pharmaceutical Ingredients (APIs) Sales, Revenue and Gross Margin (2016-2021)
6.1.4 Lonza High Potency Active Pharmaceutical Ingredients (APIs) Product Portfolio
6.1.5 Lonza Recent Developments/Updates
6.2 Novartis International AG
6.2.1 Novartis International AG Corporation Information
6.2.2 Novartis International AG Description and Business Overview
6.2.3 Novartis International AG High Potency Active Pharmaceutical Ingredients (APIs) Sales, Revenue and Gross Margin (2016-2021)
6.2.4 Novartis International AG High Potency Active Pharmaceutical Ingredients (APIs) Product Portfolio
6.2.5 Novartis International AG Recent Developments/Updates
6.3 BASF AG
6.3.1 BASF AG Corporation Information
6.3.2 BASF AG Description and Business Overview
6.3.3 BASF AG High Potency Active Pharmaceutical Ingredients (APIs) Sales, Revenue and Gross Margin (2016-2021)
6.3.4 BASF AG High Potency Active Pharmaceutical Ingredients (APIs) Product Portfolio
6.3.5 BASF AG Recent Developments/Updates
6.4 Carbogen Amcis AG
6.4.1 Carbogen Amcis AG Corporation Information
6.4.2 Carbogen Amcis AG Description and Business Overview
6.4.3 Carbogen Amcis AG High Potency Active Pharmaceutical Ingredients (APIs) Sales, Revenue and Gross Margin (2016-2021)
6.4.4 Carbogen Amcis AG High Potency Active Pharmaceutical Ingredients (APIs) Product Portfolio
6.4.5 Carbogen Amcis AG Recent Developments/Updates
6.5 Eli Lilly and Company
6.5.1 Eli Lilly and Company Corporation Information
6.5.2 Eli Lilly and Company Description and Business Overview
6.5.3 Eli Lilly and Company High Potency Active Pharmaceutical Ingredients (APIs) Sales, Revenue and Gross Margin (2016-2021)
6.5.4 Eli Lilly and Company High Potency Active Pharmaceutical Ingredients (APIs) Product Portfolio
6.5.5 Eli Lilly and Company Recent Developments/Updates
6.6 Teva Pharmaceutical Industries Ltd
6.6.1 Teva Pharmaceutical Industries Ltd Corporation Information
6.6.2 Teva Pharmaceutical Industries Ltd Description and Business Overview
6.6.3 Teva Pharmaceutical Industries Ltd High Potency Active Pharmaceutical Ingredients (APIs) Sales, Revenue and Gross Margin (2016-2021)
6.6.4 Teva Pharmaceutical Industries Ltd High Potency Active Pharmaceutical Ingredients (APIs) Product Portfolio
6.6.5 Teva Pharmaceutical Industries Ltd Recent Developments/Updates
6.7 Bristol-Myers Squibb
6.6.1 Bristol-Myers Squibb Corporation Information
6.6.2 Bristol-Myers Squibb Description and Business Overview
6.6.3 Bristol-Myers Squibb High Potency Active Pharmaceutical Ingredients (APIs) Sales, Revenue and Gross Margin (2016-2021)
6.4.4 Bristol-Myers Squibb High Potency Active Pharmaceutical Ingredients (APIs) Product Portfolio
6.7.5 Bristol-Myers Squibb Recent Developments/Updates
6.8 Pfizer Inc.
6.8.1 Pfizer Inc. Corporation Information
6.8.2 Pfizer Inc. Description and Business Overview
6.8.3 Pfizer Inc. High Potency Active Pharmaceutical Ingredients (APIs) Sales, Revenue and Gross Margin (2016-2021)
6.8.4 Pfizer Inc. High Potency Active Pharmaceutical Ingredients (APIs) Product Portfolio
6.8.5 Pfizer Inc. Recent Developments/Updates
6.9 Roche Diagnostics.
6.9.1 Roche Diagnostics. Corporation Information
6.9.2 Roche Diagnostics. Description and Business Overview
6.9.3 Roche Diagnostics. High Potency Active Pharmaceutical Ingredients (APIs) Sales, Revenue and Gross Margin (2016-2021)
6.9.4 Roche Diagnostics. High Potency Active Pharmaceutical Ingredients (APIs) Product Portfolio
6.9.5 Roche Diagnostics. Recent Developments/Updates
6.10 Hospira Inc
6.10.1 Hospira Inc Corporation Information
6.10.2 Hospira Inc Description and Business Overview
6.10.3 Hospira Inc High Potency Active Pharmaceutical Ingredients (APIs) Sales, Revenue and Gross Margin (2016-2021)
6.10.4 Hospira Inc High Potency Active Pharmaceutical Ingredients (APIs) Product Portfolio
6.10.5 Hospira Inc Recent Developments/Updates
6.11 Boehringer Ingelheim
6.11.1 Boehringer Ingelheim Corporation Information
6.11.2 Boehringer Ingelheim High Potency Active Pharmaceutical Ingredients (APIs) Description and Business Overview
6.11.3 Boehringer Ingelheim High Potency Active Pharmaceutical Ingredients (APIs) Sales, Revenue and Gross Margin (2016-2021)
6.11.4 Boehringer Ingelheim High Potency Active Pharmaceutical Ingredients (APIs) Product Portfolio
6.11.5 Boehringer Ingelheim Recent Developments/Updates
6.12 Medtronic
6.12.1 Medtronic Corporation Information
6.12.2 Medtronic High Potency Active Pharmaceutical Ingredients (APIs) Description and Business Overview
6.12.3 Medtronic High Potency Active Pharmaceutical Ingredients (APIs) Sales, Revenue and Gross Margin (2016-2021)
6.12.4 Medtronic High Potency Active Pharmaceutical Ingredients (APIs) Product Portfolio
6.12.5 Medtronic Recent Developments/Updates
6.13 Merck & Co
6.13.1 Merck & Co Corporation Information
6.13.2 Merck & Co High Potency Active Pharmaceutical Ingredients (APIs) Description and Business Overview
6.13.3 Merck & Co High Potency Active Pharmaceutical Ingredients (APIs) Sales, Revenue and Gross Margin (2016-2021)
6.13.4 Merck & Co High Potency Active Pharmaceutical Ingredients (APIs) Product Portfolio
6.13.5 Merck & Co Recent Developments/Updates
6.14 Bayer AG
6.14.1 Bayer AG Corporation Information
6.14.2 Bayer AG High Potency Active Pharmaceutical Ingredients (APIs) Description and Business Overview
6.14.3 Bayer AG High Potency Active Pharmaceutical Ingredients (APIs) Sales, Revenue and Gross Margin (2016-2021)
6.14.4 Bayer AG High Potency Active Pharmaceutical Ingredients (APIs) Product Portfolio
6.14.5 Bayer AG Recent Developments/Updates
6.15 Sigma-Aldrich Corporation
6.15.1 Sigma-Aldrich Corporation Corporation Information
6.15.2 Sigma-Aldrich Corporation High Potency Active Pharmaceutical Ingredients (APIs) Description and Business Overview
6.15.3 Sigma-Aldrich Corporation High Potency Active Pharmaceutical Ingredients (APIs) Sales, Revenue and Gross Margin (2016-2021)
6.15.4 Sigma-Aldrich Corporation High Potency Active Pharmaceutical Ingredients (APIs) Product Portfolio
6.15.5 Sigma-Aldrich Corporation Recent Developments/Updates
6.16 Sanofi Aventis.
6.16.1 Sanofi Aventis. Corporation Information
6.16.2 Sanofi Aventis. High Potency Active Pharmaceutical Ingredients (APIs) Description and Business Overview
6.16.3 Sanofi Aventis. High Potency Active Pharmaceutical Ingredients (APIs) Sales, Revenue and Gross Margin (2016-2021)
6.16.4 Sanofi Aventis. High Potency Active Pharmaceutical Ingredients (APIs) Product Portfolio
6.16.5 Sanofi Aventis. Recent Developments/Updates
7 High Potency Active Pharmaceutical Ingredients (APIs) Manufacturing Cost Analysis
7.1 High Potency Active Pharmaceutical Ingredients (APIs) Key Raw Materials Analysis
7.1.1 Key Raw Materials
7.1.2 Key Suppliers of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
7.3 Manufacturing Process Analysis of High Potency Active Pharmaceutical Ingredients (APIs)
7.4 High Potency Active Pharmaceutical Ingredients (APIs) Industrial Chain Analysis
8 Marketing Channel, Distributors and Customers
8.1 Marketing Channel
8.2 High Potency Active Pharmaceutical Ingredients (APIs) Distributors List
8.3 High Potency Active Pharmaceutical Ingredients (APIs) Customers
9 High Potency Active Pharmaceutical Ingredients (APIs) Market Dynamics
9.1 High Potency Active Pharmaceutical Ingredients (APIs) Industry Trends
9.2 High Potency Active Pharmaceutical Ingredients (APIs) Growth Drivers
9.3 High Potency Active Pharmaceutical Ingredients (APIs) Market Challenges
9.4 High Potency Active Pharmaceutical Ingredients (APIs) Market Restraints
10 Global Market Forecast
10.1 High Potency Active Pharmaceutical Ingredients (APIs) Market Estimates and Projections by Type
10.1.1 Global Forecasted Sales of High Potency Active Pharmaceutical Ingredients (APIs) by Type (2022-2027)
10.1.2 Global Forecasted Revenue of High Potency Active Pharmaceutical Ingredients (APIs) by Type (2022-2027)
10.2 High Potency Active Pharmaceutical Ingredients (APIs) Market Estimates and Projections by Application
10.2.1 Global Forecasted Sales of High Potency Active Pharmaceutical Ingredients (APIs) by Application (2022-2027)
10.2.2 Global Forecasted Revenue of High Potency Active Pharmaceutical Ingredients (APIs) by Application (2022-2027)
10.3 High Potency Active Pharmaceutical Ingredients (APIs) Market Estimates and Projections by Region
10.3.1 Global Forecasted Sales of High Potency Active Pharmaceutical Ingredients (APIs) by Region (2022-2027)
10.3.2 Global Forecasted Revenue of High Potency Active Pharmaceutical Ingredients (APIs) by Region (2022-2027)
11 Research Finding and Conclusion
12 Methodology and Data Source
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Author List
12.4 Disclaimer
List of TablesList of Tables
Table 1. Global High Potency Active Pharmaceutical Ingredients (APIs) Sales (K Units) Growth Rate Comparison by Type (2021-2027)
Table 2. Global High Potency Active Pharmaceutical Ingredients (APIs) Sales (K Units) Comparison by Application (2021-2027)
Table 3. Global High Potency Active Pharmaceutical Ingredients (APIs) Market Size by Region (US$ Million) (2016 VS 2021 VS 2027)
Table 4. Key Manufacturers High Potency Active Pharmaceutical Ingredients (APIs) Covered in This Study
Table 5. Global High Potency Active Pharmaceutical Ingredients (APIs) Sales (K Units) of Key Manufacturers (2016-2021)
Table 6. Global High Potency Active Pharmaceutical Ingredients (APIs) Sales Market Share by Manufacturers (2016-2021)
Table 7. Global High Potency Active Pharmaceutical Ingredients (APIs) Revenue (US$ Million) by Manufacturers (2016-2021)
Table 8. Global High Potency Active Pharmaceutical Ingredients (APIs) Revenue Share by Manufacturers (2016-2021)
Table 9. Global Market High Potency Active Pharmaceutical Ingredients (APIs) Average Price (USD/Unit) of Key Manufacturers (2016-2021)
Table 10. Manufacturers High Potency Active Pharmaceutical Ingredients (APIs) Manufacturing Sites and Area Served
Table 11. Manufacturers High Potency Active Pharmaceutical Ingredients (APIs) Product Type
Table 12. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 13. Global High Potency Active Pharmaceutical Ingredients (APIs) by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in High Potency Active Pharmaceutical Ingredients (APIs) as of 2020)
Table 14. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 15. Global High Potency Active Pharmaceutical Ingredients (APIs) Sales by Region (2016-2021) & (K Units)
Table 16. Global High Potency Active Pharmaceutical Ingredients (APIs) Sales Market Share by Region (2016-2021)
Table 17. Global High Potency Active Pharmaceutical Ingredients (APIs) Revenue by Region (2016-2021) & (US$ Million)
Table 18. North America High Potency Active Pharmaceutical Ingredients (APIs) Sales by Country (2016-2021) & (K Units)
Table 19. North America High Potency Active Pharmaceutical Ingredients (APIs) Sales Market Share by Country (2016-2021)
Table 20. North America High Potency Active Pharmaceutical Ingredients (APIs) Revenue by Country (2016-2021) & (US$ Million)
Table 21. North America High Potency Active Pharmaceutical Ingredients (APIs) Revenue Market Share by Country (2016-2021)
Table 22. Europe High Potency Active Pharmaceutical Ingredients (APIs) Sales by Country (2016-2021) & (K Units)
Table 23. Europe High Potency Active Pharmaceutical Ingredients (APIs) Sales Market Share by Country (2016-2021)
Table 24. Europe High Potency Active Pharmaceutical Ingredients (APIs) Revenue by Country (2016-2021) & (US$ Million)
Table 25. Europe High Potency Active Pharmaceutical Ingredients (APIs) Revenue Market Share by Country (2016-2021)
Table 26. Asia Pacific High Potency Active Pharmaceutical Ingredients (APIs) Sales by Region (2016-2021) & (K Units)
Table 27. Asia Pacific High Potency Active Pharmaceutical Ingredients (APIs) Sales Market Share by Region (2016-2021)
Table 28. Asia Pacific High Potency Active Pharmaceutical Ingredients (APIs) Revenue by Region (2016-2021) & (US$ Million)
Table 29. Asia Pacific High Potency Active Pharmaceutical Ingredients (APIs) Revenue Market Share by Region (2016-2021)
Table 30. Latin America High Potency Active Pharmaceutical Ingredients (APIs) Sales by Country (2016-2021) & (K Units)
Table 31. Latin America High Potency Active Pharmaceutical Ingredients (APIs) Sales Market Share by Country (2016-2021)
Table 32. Latin America High Potency Active Pharmaceutical Ingredients (APIs) Revenue by Country (2016-2021) & (US$ Million)
Table 33. Latin America High Potency Active Pharmaceutical Ingredients (APIs) Revenue Market Share by Country (2016-2021)
Table 34. Middle East and Africa High Potency Active Pharmaceutical Ingredients (APIs) Sales by Country (2016-2021) & (K Units)
Table 35. Middle East and Africa High Potency Active Pharmaceutical Ingredients (APIs) Sales Market Share by Country (2016-2021)
Table 36. Middle East and Africa High Potency Active Pharmaceutical Ingredients (APIs) Revenue by Country (2016-2021) & (US$ Million)
Table 37. Middle East and Africa High Potency Active Pharmaceutical Ingredients (APIs) Revenue Market Share by Country (2016-2021)
Table 38. Global High Potency Active Pharmaceutical Ingredients (APIs) Sales (K Units) by Type (2016-2021)
Table 39. Global High Potency Active Pharmaceutical Ingredients (APIs) Sales Market Share by Type (2016-2021)
Table 40. Global High Potency Active Pharmaceutical Ingredients (APIs) Revenue (Million US$) by Type (2016-2021)
Table 41. Global High Potency Active Pharmaceutical Ingredients (APIs) Revenue Share by Type (2016-2021)
Table 42. Global High Potency Active Pharmaceutical Ingredients (APIs) Price (USD/Unit) by Type (2016-2021)
Table 43. Global High Potency Active Pharmaceutical Ingredients (APIs) Sales (K Units) by Application (2016-2021)
Table 44. Global High Potency Active Pharmaceutical Ingredients (APIs) Sales Market Share by Application (2016-2021)
Table 45. Global High Potency Active Pharmaceutical Ingredients (APIs) Revenue (Million US$) by Application (2016-2021)
Table 46. Global High Potency Active Pharmaceutical Ingredients (APIs) Revenue Share by Application (2016-2021)
Table 47. Global High Potency Active Pharmaceutical Ingredients (APIs) Price (USD/Unit) by Application (2016-2021)
Table 48. Lonza Corporation Information
Table 49. Lonza Description and Business Overview
Table 50. Lonza High Potency Active Pharmaceutical Ingredients (APIs) Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021)
Table 51. Lonza High Potency Active Pharmaceutical Ingredients (APIs) Product
Table 52. Lonza Recent Developments/Updates
Table 53. Novartis International AG Corporation Information
Table 54. Novartis International AG Description and Business Overview
Table 55. Novartis International AG High Potency Active Pharmaceutical Ingredients (APIs) Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021)
Table 56. Novartis International AG High Potency Active Pharmaceutical Ingredients (APIs) Product
Table 57. Novartis International AG Recent Developments/Updates
Table 58. BASF AG Corporation Information
Table 59. BASF AG Description and Business Overview
Table 60. BASF AG High Potency Active Pharmaceutical Ingredients (APIs) Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021)
Table 61. BASF AG High Potency Active Pharmaceutical Ingredients (APIs) Product
Table 62. BASF AG Recent Developments/Updates
Table 63. Carbogen Amcis AG Corporation Information
Table 64. Carbogen Amcis AG Description and Business Overview
Table 65. Carbogen Amcis AG High Potency Active Pharmaceutical Ingredients (APIs) Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021)
Table 66. Carbogen Amcis AG High Potency Active Pharmaceutical Ingredients (APIs) Product
Table 67. Carbogen Amcis AG Recent Developments/Updates
Table 68. Eli Lilly and Company Corporation Information
Table 69. Eli Lilly and Company Description and Business Overview
Table 70. Eli Lilly and Company High Potency Active Pharmaceutical Ingredients (APIs) Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021)
Table 71. Eli Lilly and Company High Potency Active Pharmaceutical Ingredients (APIs) Product
Table 72. Eli Lilly and Company Recent Developments/Updates
Table 73. Teva Pharmaceutical Industries Ltd Corporation Information
Table 74. Teva Pharmaceutical Industries Ltd Description and Business Overview
Table 75. Teva Pharmaceutical Industries Ltd High Potency Active Pharmaceutical Ingredients (APIs) Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021)
Table 76. Teva Pharmaceutical Industries Ltd High Potency Active Pharmaceutical Ingredients (APIs) Product
Table 77. Teva Pharmaceutical Industries Ltd Recent Developments/Updates
Table 78. Bristol-Myers Squibb Corporation Information
Table 79. Bristol-Myers Squibb Description and Business Overview
Table 80. Bristol-Myers Squibb High Potency Active Pharmaceutical Ingredients (APIs) Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021)
Table 81. Bristol-Myers Squibb High Potency Active Pharmaceutical Ingredients (APIs) Product
Table 82. Bristol-Myers Squibb Recent Developments/Updates
Table 83. Pfizer Inc. Corporation Information
Table 84. Pfizer Inc. Description and Business Overview
Table 85. Pfizer Inc. High Potency Active Pharmaceutical Ingredients (APIs) Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021)
Table 86. Pfizer Inc. High Potency Active Pharmaceutical Ingredients (APIs) Product
Table 87. Pfizer Inc. Recent Developments/Updates
Table 88. Roche Diagnostics. Corporation Information
Table 89. Roche Diagnostics. Description and Business Overview
Table 90. Roche Diagnostics. High Potency Active Pharmaceutical Ingredients (APIs) Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021)
Table 91. Roche Diagnostics. High Potency Active Pharmaceutical Ingredients (APIs) Product
Table 92. Roche Diagnostics. Recent Developments/Updates
Table 93. Hospira Inc Corporation Information
Table 94. Hospira Inc Description and Business Overview
Table 95. Hospira Inc High Potency Active Pharmaceutical Ingredients (APIs) Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021)
Table 96. Hospira Inc High Potency Active Pharmaceutical Ingredients (APIs) Product
Table 97. Hospira Inc Recent Developments/Updates
Table 98. Boehringer Ingelheim Corporation Information
Table 99. Boehringer Ingelheim Description and Business Overview
Table 100. Boehringer Ingelheim High Potency Active Pharmaceutical Ingredients (APIs) Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021)
Table 101. Boehringer Ingelheim High Potency Active Pharmaceutical Ingredients (APIs) Product
Table 102. Boehringer Ingelheim Recent Developments/Updates
Table 103. Medtronic Corporation Information
Table 104. Medtronic Description and Business Overview
Table 105. Medtronic High Potency Active Pharmaceutical Ingredients (APIs) Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021)
Table 106. Medtronic High Potency Active Pharmaceutical Ingredients (APIs) Product
Table 107. Medtronic Recent Developments/Updates
Table 108. Merck & Co Corporation Information
Table 109. Merck & Co Description and Business Overview
Table 110. Merck & Co High Potency Active Pharmaceutical Ingredients (APIs) Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021)
Table 111. Merck & Co High Potency Active Pharmaceutical Ingredients (APIs) Product
Table 112. Merck & Co Recent Developments/Updates
Table 113. Bayer AG Corporation Information
Table 114. Bayer AG Description and Business Overview
Table 115. Bayer AG High Potency Active Pharmaceutical Ingredients (APIs) Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021)
Table 116. Bayer AG High Potency Active Pharmaceutical Ingredients (APIs) Product
Table 117. Bayer AG Recent Developments/Updates
Table 118. Sigma-Aldrich Corporation Corporation Information
Table 119. Sigma-Aldrich Corporation Description and Business Overview
Table 120. Sigma-Aldrich Corporation High Potency Active Pharmaceutical Ingredients (APIs) Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021)
Table 121. Sigma-Aldrich Corporation High Potency Active Pharmaceutical Ingredients (APIs) Product
Table 122. Sigma-Aldrich Corporation Recent Developments/Updates
Table 123. Sanofi Aventis. Corporation Information
Table 124. Sanofi Aventis. Description and Business Overview
Table 125. Sanofi Aventis. High Potency Active Pharmaceutical Ingredients (APIs) Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021)
Table 126. Sanofi Aventis. High Potency Active Pharmaceutical Ingredients (APIs) Product
Table 127. Sanofi Aventis. Recent Developments/Updates
Table 128. Production Base and Market Concentration Rate of Raw Material
Table 129. Key Suppliers of Raw Materials
Table 130. High Potency Active Pharmaceutical Ingredients (APIs) Distributors List
Table 131. High Potency Active Pharmaceutical Ingredients (APIs) Customers List
Table 132. High Potency Active Pharmaceutical Ingredients (APIs) Market Trends
Table 133. High Potency Active Pharmaceutical Ingredients (APIs) Growth Drivers
Table 134. High Potency Active Pharmaceutical Ingredients (APIs) Market Challenges
Table 135. High Potency Active Pharmaceutical Ingredients (APIs) Market Restraints
Table 136. Global High Potency Active Pharmaceutical Ingredients (APIs) Sales Forecast by Type (2022-2027) & (K Units)
Table 137. Global High Potency Active Pharmaceutical Ingredients (APIs) Sales Market Share Forecast by Type (2022-2027)
Table 138. Global High Potency Active Pharmaceutical Ingredients (APIs) Revenue Forecast by Type (2022-2027) & (US$ Million)
Table 139. Global High Potency Active Pharmaceutical Ingredients (APIs) Revenue Market Share Forecast by Type (2022-2027)
Table 140. Global High Potency Active Pharmaceutical Ingredients (APIs) Sales Forecast by Application (2022-2027) & (K Units)
Table 141. Global High Potency Active Pharmaceutical Ingredients (APIs) Sales Market Share Forecast by Application (2022-2027)
Table 142. Global High Potency Active Pharmaceutical Ingredients (APIs) Revenue Forecast by Application (2022-2027) & (US$ Million)
Table 143. Global High Potency Active Pharmaceutical Ingredients (APIs) Revenue Market Share Forecast by Application (2022-2027)
Table 144. Global High Potency Active Pharmaceutical Ingredients (APIs) Sales Forecast by Region (2022-2027) & (K Units)
Table 145. Global High Potency Active Pharmaceutical Ingredients (APIs) Sales Market Share Forecast by Region (2022-2027)
Table 146. Global High Potency Active Pharmaceutical Ingredients (APIs) Revenue Forecast by Region (2022-2027) & (US$ Million)
Table 147. Global High Potency Active Pharmaceutical Ingredients (APIs) Revenue Market Share Forecast by Region (2022-2027)
Table 148. Research Programs/Design for This Report
Table 149. Key Data Information from Secondary Sources
Table 150. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of High Potency Active Pharmaceutical Ingredients (APIs)
Figure 2. Global High Potency Active Pharmaceutical Ingredients (APIs) Market Share by Type in 2020 & 2027
Figure 3. Synthetic Product Picture
Figure 4. Biotech Product Picture
Figure 5. Global High Potency Active Pharmaceutical Ingredients (APIs) Market Share by Application in 2020 & 2027
Figure 6. Oncology
Figure 7. Hormonal
Figure 8. Glaucoma
Figure 9. Others
Figure 10. Global High Potency Active Pharmaceutical Ingredients (APIs) Revenue, (US$ Million), 2016 VS 2021 VS 2027
Figure 11. Global High Potency Active Pharmaceutical Ingredients (APIs) Market Size 2016-2027 (US$ Million)
Figure 12. Global High Potency Active Pharmaceutical Ingredients (APIs) Sales 2016-2027 (K Units)
Figure 13. Global High Potency Active Pharmaceutical Ingredients (APIs) Market Size Market Share by Region: 2016 VS 20210 VS 2027
Figure 14. High Potency Active Pharmaceutical Ingredients (APIs) Sales Share by Manufacturers in 2020
Figure 15. Global High Potency Active Pharmaceutical Ingredients (APIs) Revenue Share by Manufacturers in 2020
Figure 16. The Global 5 and 10 Largest High Potency Active Pharmaceutical Ingredients (APIs) Players: Market Share by Revenue in 2020
Figure 17. High Potency Active Pharmaceutical Ingredients (APIs) Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2016 VS 2021
Figure 18. Global High Potency Active Pharmaceutical Ingredients (APIs) Sales Market Share by Region (2016-2021)
Figure 19. Global High Potency Active Pharmaceutical Ingredients (APIs) Sales Market Share by Region in 2020
Figure 20. Global High Potency Active Pharmaceutical Ingredients (APIs) Revenue Market Share by Region (2016-2021)
Figure 21. Global High Potency Active Pharmaceutical Ingredients (APIs) Revenue Market Share by Region in 2020
Figure 22. U.S. High Potency Active Pharmaceutical Ingredients (APIs) Revenue Growth Rate (2016-2021) (US$ Million)
Figure 23. Canada High Potency Active Pharmaceutical Ingredients (APIs) Revenue Growth Rate (2016-2021) (US$ Million)
Figure 24. Germany High Potency Active Pharmaceutical Ingredients (APIs) Revenue Growth Rate (2016-2021) (US$ Million)
Figure 25. France High Potency Active Pharmaceutical Ingredients (APIs) Revenue Growth Rate (2016-2021) (US$ Million)
Figure 26. U.K. High Potency Active Pharmaceutical Ingredients (APIs) Revenue Growth Rate (2016-2021) (US$ Million)
Figure 27. Italy High Potency Active Pharmaceutical Ingredients (APIs) Revenue Growth Rate (2016-2021) (US$ Million)
Figure 28. Russia High Potency Active Pharmaceutical Ingredients (APIs) Revenue Growth Rate (2016-2021) (US$ Million)
Figure 29. China High Potency Active Pharmaceutical Ingredients (APIs) Revenue Growth Rate (2016-2021) (US$ Million)
Figure 30. Japan High Potency Active Pharmaceutical Ingredients (APIs) Revenue Growth Rate (2016-2021) (US$ Million)
Figure 31. South Korea High Potency Active Pharmaceutical Ingredients (APIs) Revenue Growth Rate (2016-2021) (US$ Million)
Figure 32. India High Potency Active Pharmaceutical Ingredients (APIs) Revenue Growth Rate (2016-2021) (US$ Million)
Figure 33. Australia High Potency Active Pharmaceutical Ingredients (APIs) Revenue Growth Rate (2016-2021) (US$ Million)
Figure 34. Taiwan High Potency Active Pharmaceutical Ingredients (APIs) Revenue Growth Rate (2016-2021) (US$ Million)
Figure 35. Indonesia High Potency Active Pharmaceutical Ingredients (APIs) Revenue Growth Rate (2016-2021) (US$ Million)
Figure 36. Thailand High Potency Active Pharmaceutical Ingredients (APIs) Revenue Growth Rate (2016-2021) (US$ Million)
Figure 37. Malaysia High Potency Active Pharmaceutical Ingredients (APIs) Revenue Growth Rate (2016-2021) (US$ Million)
Figure 38. Philippines High Potency Active Pharmaceutical Ingredients (APIs) Revenue Growth Rate (2016-2021) (US$ Million)
Figure 39. Vietnam High Potency Active Pharmaceutical Ingredients (APIs) Revenue Growth Rate (2016-2021) (US$ Million)
Figure 40. Mexico High Potency Active Pharmaceutical Ingredients (APIs) Revenue Growth Rate (2016-2021) (US$ Million)
Figure 41. Brazil High Potency Active Pharmaceutical Ingredients (APIs) Revenue Growth Rate (2016-2021) (US$ Million)
Figure 42. Argentina High Potency Active Pharmaceutical Ingredients (APIs) Revenue Growth Rate (2016-2021) (US$ Million)
Figure 43. Turkey High Potency Active Pharmaceutical Ingredients (APIs) Revenue Growth Rate (2016-2021) (US$ Million)
Figure 44. Saudi Arabia High Potency Active Pharmaceutical Ingredients (APIs) Revenue Growth Rate (2016-2021) (US$ Million)
Figure 45. U.A.E High Potency Active Pharmaceutical Ingredients (APIs) Revenue Growth Rate (2016-2021) (US$ Million)
Figure 46. Sales Market Share of High Potency Active Pharmaceutical Ingredients (APIs) by Type (2016-2021)
Figure 47. Sales Market Share of High Potency Active Pharmaceutical Ingredients (APIs) by Application (2016-2021)
Figure 48. Sales Market Share of High Potency Active Pharmaceutical Ingredients (APIs) by Application in 2020
Figure 49. Revenue Share of High Potency Active Pharmaceutical Ingredients (APIs) by Application (2016-2021)
Figure 50. Revenue Share of High Potency Active Pharmaceutical Ingredients (APIs) by Application in 2020
Figure 51. Manufacturing Cost Structure of High Potency Active Pharmaceutical Ingredients (APIs)
Figure 52. Manufacturing Process Analysis of High Potency Active Pharmaceutical Ingredients (APIs)
Figure 53. High Potency Active Pharmaceutical Ingredients (APIs) Industrial Chain Analysis
Figure 54. Channels of Distribution
Figure 55. Distributors Profiles
Figure 56. Bottom-up and Top-down Approaches for This Report
Figure 57. Data Triangulation
Figure 58. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
